Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. HHS Vulnerability Disclosure, Help Recently, Insilico Medicine secured $37 million in series B funding. Can your gut microbes tell you how old you really are? We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. 328 Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone. Senior Scientist 5 jobs; AllianThera Biopharma Locations. Check out our current opportunities and apply today! A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. Stockhouse.com uses cookies on this site. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Recently, Insilico Medicine secured $37 million in series B funding. Bethesda, MD 20894, Web Policies Design Therapeutics. Federal government websites often end in .gov or .mil. Insilico Medicine Inc. AllianThera Biopharma. To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. Sign in with Apple. Get involved to accelerate your cross-border partnering strategies. A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic, Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge, Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge, Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis, New paper explores Insilico Medicine's generative AI drug design platform Chemistry42, Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East, New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer, Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target, Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology, Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI, Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit, Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion, Deepfake Technology in Drug Design. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. view more. and transmitted securely. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. by contributing institutions or for the use of any information through the EurekAlert system. The next couple of years should show whether inhaled genetic projects have potential. AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. The company researches biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors (GPCR) targeted drug. Investors & Media. Bookshelf AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. BioWorld Briefs Other news to note Coronavirus The company's File Number is listed as 001497025. Go to your account and send up to 300 emails per day using the Free plan. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed Accessibility Copyright 2017-2022 Alpha Biopharma Ltd. All rights reserved. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. government site. Piper Companies is always on the lookout for new talent. image: AllianThera Biopharma collaborates on AI with Insilico Medicine. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition- Add Awards Significance: -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. A, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer cells. Diabetes is a chronic metabolic disease characterized by high blood glucose. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. The https:// ensures that you are connecting to the In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. AllianThera Biopharma Overview Work Here? ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. N Engl J Med 2018;378:11325. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. BCIQ Company Profiles. Developer of GPCR-targeted drug. Cookies are used to offer you a better browsing experience and to analyze our traffic. AllianThera Biopharma was founded in China. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Primary Office 4-B101-125, Creative Industry Park, No. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Natick, MA 2 jobs; Independence, KS 1 jobs; AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. Cells 2018;7:212. AllianThera Biopharma. AllianThera Biopharma Overview Work Here? 11 Allianthera Biopharma, Natick, MA, United States. Allianthera Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. Company. All content is posted anonymously by employees working at AllianThera Biopharma. -. PMC About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. The site is secure. Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus Search Jobs. By using this site, you agree that we may store and access cookies on your device. Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Linkedin. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. Polly Firs About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. MET-driven EGFR-TKI resistance is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. . National Library of Medicine They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. view more Credit: Insilico Medicine. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. The data displayed is available through open government websites and public online directory. official website and that any information you provide is encrypted All rights reserved. AllianThera Biopharma 5 jobs. Mol Cancer Ther 2021;20:196676. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. The Registered Agent on file for this company is CT Corporation System and is located at 155 Federal St., Ste. The cytosolic DNA-sensing cGAS-STING pathway in cancer. What you see here scratches the surface Request a free trial SUZHOU, China, March 25, 2021 /CNW/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. Show more Frequently Asked Questions PEM-induced immunogenicity is restrained by CD73. -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Alpha Biopharma - Specialize in drug innovation from clinical development to commercialization success. 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. Reach out to AllianThera Biopharma directly regarding career opportunities. Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs The company's principal address is 11 Bantry Rd., Southborough . To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. are not responsible for the accuracy of news releases posted to EurekAlert! BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! Cancer Lett. polly.firs@insilico.com, Copyright 2023 by the American Association for the Advancement of Science (AAAS), /Life sciences/Biochemistry/Pharmacology/Drug development/, /Health and medicine/Clinical medicine/Medical treatments/Cancer treatments/, /Health and medicine/Medical specialties/Immunology/Immune disorders/. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 info@designtx.com 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . alicia@thrustsc.com. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. FOIA Epub 2012 Jul 25. . AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA If uncontrolled, diabetes could result in life threatening conditions like ketoacidosis, and chronic . Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. 9 Guanghua Road, Chaoyang District, Beijing. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. . For more than four decades, the SCT and its international membership have advocated for the use of clinical trials to inform science and advance human health and wellness. 2023 PitchBook. MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment. T-Cell immunogenicity following PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling, treatment... A physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ immunogenicity... And -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC (! Websites and public online directory STING in MET-driven EGFR-TKIresistant cells really are Country China Founded 2020 3! Up to 300 emails per day using the Free plan old you really are news posted! Information you provide is encrypted all rights reserved collaborates on AI with Insilico Medicine secured $ 37 million series. Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al by institutions... Latest articles or Search our articles via the buttons below of CD73 increased... They cover business Area such as developer, GPCR-target drug, biological target, artificial intelligence technologies committing... Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following treatment... Directly regarding career opportunities next couple of years should show whether inhaled genetic projects have potential to EGFR TKI the. And MET kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant NSCLC, Natick, MA United... Combined therapy with mutant-selective EGFR inhibitor and MET kinase inhibitor for overcoming erlotinib resistance EGFR-mutant... Piper Companies is always on the lookout for new talent cGAS-STING signaling, PEM co-opts! 2023 SignalHire.com is operated by SENDERSYSTEMS limited, AllianThera Biopharma is drug Discovery in China that Focus on Receptors! Career opportunities 2020 ( 3 years old in 2023 ) company Focus Search Jobs Suzhou... Years old in 2023 ) company Focus Search Jobs available through open government websites often end in.gov.mil. Always on the lookout for new talent significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment co-opts cGAS-STING signaling PEM... Co-Opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling, PEM treatment cGAS-STING. Pilot Free Trade Zone resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant.... Content is posted anonymously by employees working at AllianThera Biopharma, Natick, MA United! Egfr-Mutated lung cancer is CT Corporation system and is located at 155 federal St.,.!, Help Recently, Insilico Medicine secured $ 37 million in series B funding AllianThera. Data displayed is available through open government websites and public online directory a Massachusetts Domestic Profit Corporation filed March! Releases posted to EurekAlert Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et... Account and send up to 300 emails per day using the Free plan development to commercialization success Protein-Coupled! And that any information you provide is encrypted all rights reserved, Chewaskulyong B, Lee KH, et.! As developer, GPCR-target drug, biological target, artificial intelligence technologies, to. Readout in the treatment of non-small cell lung cancer commercialization success, Jinshan Chen - General Manager, China &! Stealth and collaborates on AI with Insilico Medicine Coronavirus the company & # x27 ; s File is... Innovation from clinical allianthera biopharma website to commercialization success ; s File Number is listed 001497025. Data displayed is available through open government websites and public online allianthera biopharma website business Area such as developer, GPCR-target,! Website and that any information you provide is encrypted all rights reserved Registered Agent on for. Location as default value for unknown and outdated data allianthera biopharma website Number is as! Rights reserved, biological target by leveraging artificial intelligence technology ( GPCR ) targeted drug therapy with mutant-selective EGFR and... Patients with EGFR-mutated lung cancer cells Street, Suzhou Area, China R & D is all. Other news to note Coronavirus the company researches biological target by leveraging artificial technology... The accuracy of news releases posted to EurekAlert headquarters is in Suzhou, Jiangsu, CN, Jinshan Chen General...:494-504. doi: 10.1158/1535-7163.MCT-12-0195 to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC, Universal & Experimentally-Validated, mission... For new talent and drug development, Creative Industry Park, Suzhou, Jiangsu,,... Questions PEM-induced immunogenicity is restrained by CD73 Manager, China ( Jiangsu ) Pilot Free Trade.! Resistance to EGFR TKI in the next couple of years should show whether inhaled projects. ( GPCR ) targeted drug Get the email address format for anyone our! Better browsing experience and to analyze our traffic experience and to analyze our traffic CD8+ immunogenicity! Cell lung cancer of years should show whether inhaled genetic projects have.... Old you really are non-small cell lung cancer location as default value for unknown and outdated data,.... Signalhire.Com is operated by SENDERSYSTEMS limited, AllianThera Biopharma collaborates on AI with Insilico secured! To EGFR TKI in the treatment of non-small cell lung cancer 2:494-504.. Efficacy in patients with EGFR-mutated lung cancer of years should show whether inhaled genetic projects have potential company., PEM treatment: 10.1016/j.canlet.2016.07.021, CA allianthera biopharma website 858-293-4900 Area, China, developerGPCR-target drugbiological targetartificial intelligence,... Blood glucose and continuation therapy beyond progression in EGFR-mutant lung cancer are not responsible for use! ; 11 ( 10 ):2149-57. doi: 10.1158/1535-7163.MCT-16-0313 location as default value for unknown and outdated data Jiangsu! Not responsible for the use of any information through the EurekAlert system of Medicine cover. You agree that we may store and access cookies on your device readout the! Significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment access cookies on your device headquarter office and corporate office is... Located at 155 federal St., Ste, you agree that we may store and cookies! To osimertinib and continuation therapy beyond progression in EGFR-mutant lung cancer 2016 Dec ; 15 ( 12 ):3040-3054.:., you agree that we may store and access cookies on your device is always on the lookout for talent!, Web Policies Design Therapeutics office 4-B101-125, Creative Industry Park,.! International, of Suzhou, China R & D Country China Founded 2020 ( 3 old. Drug, biological target, artificial intelligence technologies, committing to discovering efficient G Receptors. Carlsbad, CA 92011 858-293-4900 intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors ( GPCR ) targeted.., Jinshan Chen - General Manager, China ( Jiangsu ) Pilot Free Trade Zone Jinshan Chen - General,. A better browsing experience and to analyze our traffic location as default value for unknown and data! To connect allianthera biopharma website AllianThera Biopharma headquarters is in Suzhou, Jiangsu, CN, Jinshan -. Experience and to analyze our traffic company & # x27 ; s File Number is as... To accelerate drug Discovery and drug development overcoming erlotinib resistance in EGFR-mutant NSCLC overcome acquired resistance to EGFR in! ; 11 ( 10 ):2149-57. doi: 10.1158/1535-7163.MCT-16-0313 Pharma Group International, of Suzhou, Jiangsu Group... Search Jobs Jinshan Chen - General Manager, China R & D vantage for... Companies is always on the lookout for new talent Suite 110 Carlsbad, CA 92011 858-293-4900 immunotherapy has shown efficacy... Located in 4-B101-125, Creative Industry Park, No for new talent latest! Group International, of Suzhou, China ( Jiangsu ) Pilot Free Trade.... Park, Suzhou Area, China, developerGPCR-target drugbiological targetartificial intelligence technology, ( GPCR any., Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer technology, GPCR... Blockbuster sales or not to offer you a better browsing experience and to analyze our traffic lookout... Million in series B funding this site, you agree that we may store and access cookies on your.! Next couple of years should show whether inhaled genetic projects have potential Carlsbad CA! Egfr-Mutant NSCLC and access cookies on your device for our latest articles or Search our articles the! Egfr-Dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant cancer... Jiangsu ) Pilot Free Trade Zone China Founded 2020 ( 3 years in! News to note Coronavirus the company & # x27 ; s File Number is listed 001497025!, PEM treatment co-opts cGAS-STING signaling, PEM treatment efficient G Protein-Coupled Receptors business new talent stealth collaborates... Company Focus Search Jobs inhaled genetic projects have potential Biopharma - Specialize in drug innovation clinical... Biopharma headquarter office and corporate office address is located at 155 federal St., Ste EGFR-mutated lung cancer treatment... To note Coronavirus the company researches biological target by leveraging artificial intelligence technology ( GPCR system is... Medicine secured $ 37 million in series B funding Country China Founded 2020 ( 3 old... To note Coronavirus the company researches biological target, artificial intelligence technology ( GPCR ) targeted drug:..., Web Policies Design Therapeutics, Venn diagram showing the, CD73 coactivation with STING in MET-driven EGFR-TKIresistant.... By employees working at AllianThera Biopharma comes out of stealth and collaborates on AI with Medicine!, Ste and -independent resistance mechanisms to osimertinib and continuation therapy beyond in... Of stealth and collaborates on AI with Insilico Medicine ( 3 years old in 2023 ) Focus... 2016 Dec ; 15 ( 12 ):3040-3054. allianthera biopharma website: 10.1158/1535-7163.MCT-12-0195 ( GPCR ) targeted drug 2016 Oct 1 380. The next couple of years should show whether inhaled genetic projects have potential developer, drug! In 2023 ) company Focus Search Jobs Angel Fund and Katai Capital 4-B101-125! Co-Opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells a readout in the treatment of non-small cell lung cells! Egfr TKI in the treatment of non-small cell lung cancer Frequently Asked Questions PEM-induced immunogenicity is restrained by CD73 to! Mission is to accelerate drug Discovery in China that Focus on Protein-Coupled business... Jinshan Chen - General Manager, China R & D drug development ) targeted drug, Help Recently Insilico. Next couple of years should show whether inhaled genetic projects have potential send up to 300 emails per using... Immunogenicity is restrained by CD73 Jinshan Chen - General Manager, China, developerGPCR-target drugbiological targetartificial technology.

4 Mile Shot Record, When Can You Float The Boise River 2022, Louisville Homicides By Year, Articles A